Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (484)	1/29/1999 7:36:00 AM
From: Micawber	Read Replies (1) \| Respond to of 1073

Rick: Have been a lurker for quite some time. Your analysis and discussion is both incredibly insightful and entertaining. I have never seen you discuss ISIP, and would be interested in your opinion. TIA. BPG

To: scaram(o)uche who wrote (484)	1/29/1999 12:26:00 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 1073

Rick; The V.P., where did he go? Thanks; Steve

To: scaram(o)uche who wrote (484)	1/31/1999 11:42:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1073

OK RICK you take the fifth on LJPC. I take it you are familiar with the Lupus clinicals? Fascinating if they could actually treat the actual disease as opposed to a specific indication. Given the complex nature of Lupus I have my reservations on the success of treating the entire disease state. Call me a skeptic. Anyway are you familiar with GNLB's Lupus clinicals? It doesn't look like a major revenue generator. But any success is a noteworthy effort. Maybe I am underestimating GNLB's Lupus product. But with so many indications associated with the disease is it really addressing the major issues with the disease state? Jeff